Hussman Strategic Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Hussman Strategic Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.64M	Buy	+147,000	New	+$2.78M	0.61%	59
2026 Q1	–	Sell	-63,000	Closed	-$1.36M	–	330
2025 Q4	$1.36M	Sell	63,000 -21,000	-25%	-$443K	0.33%	139
2025 Q3	$1.62M	Buy	84,000 +21,000	+33%	+$374K	0.35%	131
2025 Q2	$1.08M	Buy	63,000 +52,500	+500%	+$2.24M	0.25%	138
2025 Q1	$670K	Buy	+10,500	New	+$1.11M	0.16%	184

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hussman Strategic Advisors's SRPT Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 147,000 shares worth $2.64M. The stake represents 0.61% of the portfolio and ranks #59 among its holdings. This is a return to the name: Hussman Strategic Advisors previously reported a position in SRPT as recently as Q4 2025.

Hussman Strategic Advisors first reported a position in SRPT in Q1 2025 and has held it in 5 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Hussman Strategic Advisors held 147,000 shares of Sarepta Therapeutics worth $2.64M as of Q2 2026.
Sarepta Therapeutics was a new Hussman Strategic Advisors position in Q2 2026.
Sarepta Therapeutics made up 0.61% of Hussman Strategic Advisors's portfolio in Q2 2026, its #59 holding.
Hussman Strategic Advisors first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 5 quarters since.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.